Fareon (formerly Humanity Neurotech) targets neuroinflammation itself rather than a specific circuit or symptom, using a proprietary microtesla magnetic field distinct from standard TMS's higher-power pulses, positioning it as a biophysics platform play across conditions like long COVID brain fog, post-concussion syndrome, and bipolar disorder rather than a single-indication device. Peer-reviewed preclinical evidence (Sanford Burnham Prebys collaboration) and emerging biomarker data (reduced inflammation, lower predicted brain age) give it earlier mechanistic validation than most at-home neuromodulation devices, though clinical efficacy in humans is still exploratory.